Form 8-K - Current report:
SEC Accession No. 0001193125-22-161149
Filing Date
2022-05-26
Accepted
2022-05-26 17:06:15
Documents
14
Period of Report
2022-05-26
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d290066d8k.htm   iXBRL 8-K 23069
2 EX-99.1 d290066dex991.htm EX-99.1 23260
6 GRAPHIC g290066g0526194117715.jpg GRAPHIC 4551
  Complete submission text file 0001193125-22-161149.txt   181383

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA tpst-20220526.xsd EX-101.SCH 2864
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE tpst-20220526_lab.xml EX-101.LAB 17996
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE tpst-20220526_pre.xml EX-101.PRE 11267
8 EXTRACTED XBRL INSTANCE DOCUMENT d290066d8k_htm.xml XML 3416
Mailing Address 7000 SHORELINE COURT SUITE 275 SOUTH SAN FRANCISCO CA 94080
Business Address 7000 SHORELINE COURT SUITE 275 SOUTH SAN FRANCISCO CA 94080 415-798-8589
Tempest Therapeutics, Inc. (Filer) CIK: 0001544227 (see all company filings)

EIN.: 451472564 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-35890 | Film No.: 22971203
SIC: 2834 Pharmaceutical Preparations